Replicor publishes data on the activity and safety of amphipathic DNA polymers (APs) in cytomegalovirus infection.
December 2, 2009 – Data generated in collaboration with the Cincinnati Children’s Hospital and funded in part by the NIH was published in Virology Journal. This article presents data that demonstrates that several different amphipathic DNA polymers (APs) are highly effective in protecting mice from developing CMV infections. APs were effective whether administered parenterally or orally (when formulated with an intestinal permeation enhancer). The AP REP 9C was very well tolerated and was shown to have negligible immunostimulatory activity in vivo, which has been reported for other compounds in the same chemical class. APs may be an important new treatment for the prophylaxis and therapy of CMV infections.